Scarica l'app Stockscreener
16.58
3.94%
-0.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$17.26
Aprire:
$17.4
Volume 24 ore:
2.08M
Relative Volume:
0.80
Capitalizzazione di mercato:
$12.86B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-11.48
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
+6.90%
1M Prestazione:
-0.06%
6M Prestazione:
-20.86%
1 anno Prestazione:
-19.51%
Intervallo 1D:
$16.38
$17.51
Intervallo di 1 settimana:
$15.36
$18.24
Portata 52W:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.58 | 12.86B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance
Summit Therapeutics (SMMT) climbs 15.4% ahead of pipeline Q2 updates - msn.com
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics to present ivonescimab data at ELCC 2026 - StreetInsider
Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026 - marketscreener.com
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire
Summit Therapeutics (NASDAQ:SMMT) Raised to Strong-Buy at Truist Financial - MarketBeat
What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30 - Insider Monkey
Aug Sectors: Can Summit Therapeutics Inc be the next market leader - baoquankhu1.vn
5 Large Cap Stocks Under $30 With Huge Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Insider Monkey
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - Yahoo Finance
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's
Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - stockstotrade.com
Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - MarketBeat
Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN
Axsome Therapeutics faces competition amid FDA review risk for Summit's ivonescimab - Intellectia AI
Summit Therapeutics (SMMT) Stock Price Prediction for 2026, 2030-2040 - Traders Union
347,241 Shares in Summit Therapeutics PLC $SMMT Acquired by Tudor Investment Corp ET AL - MarketBeat
Responsive Playbooks and the SMMT Inflection - Stock Traders Daily
Trade Recap: Does Summit Therapeutics Inc have a sustainable dividend2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
SMMT PE Ratio & Valuation, Is SMMT Overvalued - Intellectia AI
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Jefferies downgrades Summit Therapeutics (SMMT) - MSN
Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st
SMMT Downgraded by Jefferies, Price Target Slashed by 64% | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat
Summit Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
SMMT SEC FilingsSummit Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherTime to Buy? - MarketBeat
How correlated is Summit Therapeutics Inc to the S P5002026 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
WINTON GROUP Ltd Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Understanding the Setup: (SMMT) and Scalable Risk - Stock Traders Daily
Summit Therapeutics at The Citizens Life Sciences Conference: Strategic Insights on Ivonescimab - Investing.com Nigeria
Earnings Report: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Portfolio Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Earnings Recap: How correlated is Summit Therapeutics Inc to the S P5002026 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Summit Therapeutics’ Earnings Call Highlights OS Hurdles - The Globe and Mail
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Zacks Research to Hold Rating - MarketBeat
Summit Therapeutics (SMMT) ends 2025 with strong cash reserves and increased clinical investment - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Outlook: Can Summit Therapeutics Inc stock outperform in a bear marketDollar Strength & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Summit Therapeutics (SMMT) Is Down 6.3% After Wider 2025 Loss and ESOP Shelf Filing - simplywall.st
Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st
Rafferty Asset Management LLC Purchases 140,323 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Finviz
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
3.03%
2.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):